It is currently Sat Feb 17, 2018 3:42 pm

News News of ThisIsMS

Site map of ThisIsMS » Forum : ThisIsMS

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

1974 study: Mg deficit: poss cause of refractory low vit B1

happened on this tiny old study while looking at something else altogether:

Magnesium deficiency: a possible cause of thiamine refractoriness in Wernicke-Korsakoff encephalopathy
http://jnnp.bmj.com/content/37/8/959.short

The determination of blood transketolase before and serially after thiamine administration, and the response of clinical symptomatology after thiamine are reported in two normomagnesaemic patients and one hypomagnesaemic patient with acute Wernicke-Korsakoff encephalopathy. The response of the depressed blood transketolase and the clinical symptoms was ...
Read more : 1974 study: Mg deficit: poss cause of refractory low vit B1 | Views : 334 | Replies : 0 | Forum : Natural Approach


MRI dain bramage

https://www.youtube.com/watch?v=6X2HA0895HU I found a series of Ohio State lectures on MS. In this lecture someone in the audience asked whether MRI could cause brain damage. Another audience member piped in that a psychic lost her psychic abilities after an MRI, sued and won!
Read more : MRI dain bramage | Views : 388 | Replies : 0 | Forum : General Discussion


Ocrelizumab is granted EU licence for PPMS and RRMS

Ocrelizumab is granted EU licence for primary progressive and relapsing remitting MS

The European Commission (EC) has granted a licence for the use of ocrelizumab, also known as Ocrevus, in people with primary progressive multiple sclerosis (PPMS) and relapsing remitting multiple sclerosis (RRMS)…Read more - http://www.ms-uk.org/ocrelizumab-granted-eu-licence-primary-progressive-and-relapsing-remitting-ms

Image
Read more : Ocrelizumab is granted EU licence for PPMS and RRMS | Views : 421 | Replies : 0 | Forum : Ocrevus (Ocrelizumab)


New restrictions enforced on MS drug daclizumab

Back in July 2017, the Medical and Healthcare products Regulatory Agency (MHRA) highlighted restrictions on the use of daclizumab (Zinbryta) for relapsing remitting multiple sclerosis (RRMS) during an urgent EU review into the risk of severe liver injury... Read more - http://www.ms-uk.org/new-restrictions-enforced-ms-drug-daclizumab

Image
Read more : New restrictions enforced on MS drug daclizumab | Views : 333 | Replies : 0 | Forum : General Discussion


An optimistic review of the MS research status

It is nice to see an optimistic point of view from time to time, even though they still do not know what MS is.

Advances in multiple sclerosis: from reduced relapses to remedies

https://www.sciencedirect.com/science/a ... 2217304179

Progress in multiple sclerosis research continues at an impressive pace, with contributions from basic science, translational research, and experimental therapeutics. Several publications in the past year have had a major impact on both ...
Read more : An optimistic review of the MS research status | Views : 375 | Replies : 0 | Forum : General Discussion


From the herpes virus research front (HERV)

Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder.

https://www.ncbi.nlm.nih.gov/pubmed/29204291

Abstract
Background:


A specific humoral immune response against HERV-W envelope surface (env-su) glycoprotein antigens has been reported in serum of patients with multiple sclerosis (MS). However, it has not been evaluated to date in patients with neuromyelitis optica spectrum disorder (NMOSD).
Objective:

The objective of this paper is to investigate whether antibody (Ab) ...
Read more : From the herpes virus research front (HERV) | Views : 371 | Replies : 0 | Forum : MS Etiology and Pathogenesis


Jugular Anomalies in MS associated with collateral flow

Jugular Anomalies in Multiple Sclerosis Are Associated with Increased Collateral Venous Flow

http://www.ajnr.org/content/early/2017/05/25/ajnr.A5219

CONCLUSIONS: Compared with healthy controls, patients with MS exhibit reduced venous flow in the main extracerebral drainage vein (internal jugular vein). In contrast, flow in the paraspinal venous collaterals is elevated in patients with MS and exacerbated by venous stenosis. Collateral drainage may be a compensatory response to internal jugular vein flow reduction.


slamming the zinc reference range

they say zinc just gradually 'gets lower' as part of the aging process. but what does that mean exactly? lower than what? how do we know when to take action?

to my mind, zinc (and other) 'normal' ranges are massively and ultimately unethically deceptive

case in point. here is a selection of zinc reference or normal ranges

Zinc, Serum
https://www.mayomedicallaboratories.com ... etive/8620
Normal serum zinc is 0.66 to 1.10 ...
Read more : slamming the zinc reference range | Views : 347 | Replies : 0 | Forum : Natural Approach


Nystagmus

I have a question about nystagmus. I tend to notice mine when I am really focusing on something, like when I am reading, for example, and my eyes will jerk left to right really quickly. Sometimes they'll just jerk once or twice, and sometimes they'll go back and forth a few times before they stop. I don't remember when this started, but I do know it's been happening for awhile. My mother never has this, ...
Read more : Nystagmus | Views : 389 | Replies : 3 | Forum : General Discussion


Rituximab ‘superior to all other DMTs...'

Rituximab ‘superior to all other DMT in terms of drug discontinuation’ study finds

Scientists have conducted a study that looks at how traditional initial disease modifying treatment (DMT) choices, including dimethyl fumarate, fingolimod, or natalizumab compare with rituximab in relapsing remitting multiple sclerosis (RRMS) in terms of drug discontinuation and clinical efficacy…Read more - http://www.ms-uk.org/rituximab-superior-all-other-dmt-terms-drug-discontinuation-study-finds

Image
Read more : Rituximab ‘superior to all other DMTs...' | Views : 428 | Replies : 0 | Forum : Rituxan (Rituximab)


 

Login  •  Register


Statistics

Total posts 242175 • Total topics 26534 • Total members 17713


Contact us | Terms of Service